{"id":361215,"date":"2010-02-25T05:40:10","date_gmt":"2010-02-25T10:40:10","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=65119"},"modified":"2010-02-25T05:40:10","modified_gmt":"2010-02-25T10:40:10","slug":"anadys-hep-c-drug-shows-promise-synthetic-genomics-recruits-illumina-exec-proacta-gets-funds-more-san-diego-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/361215","title":{"rendered":"Anadys Hep C Drug Shows Promise, Synthetic Genomics Recruits Illumina Exec, ProActa Gets Funds, & More San Diego Life Sciences News"},"content":{"rendered":"\n
Roundup<\/a>, Life Sciences<\/a>, Biotech<\/a><\/div>\n

\t\tDenise Gellene wrote:<\/strong><\/p>\n

There was a smorgasbord of announcements in the last week. Get your fill here.<\/p>\n

—Anadys Pharmaceuticals<\/strong> (NASDAQ: ANDS<\/a>) said preliminary findings from a mid-stage trial <\/a>in hepatitis C patients showed that a drug cocktail consisting of its experimental drug ANA598, interferon, and ribavirin was about as effective after 12 weeks as interferon and ribavirin alone.<\/p>\n

—Ocera Therapeutics<\/strong> CEO Laurent Fischer tells Luke that the San Diego biotech should be more attractive to investors now <\/a>that an FDA advisory panel has recommended approval of a rival drug from Salix Pharmaceuticals of North Carolina. The two companies are developing drugs for brain damage caused by liver failure.<\/p>\n

—National Institutes of Health Director Francis Collins<\/strong> told Bruce that cancer and certain types of mental illness are diseases that appear ripe for research breakthroughs.<\/a> He was in San Diego last week for the annual meeting of the American Association for the Advancement of Science.<\/p>\n

—A new organization, the San Diego Entrepreneurs Exchange<\/strong>, provides information, advice and support <\/a>to entrepreneurs at early-stage companies, particularly those\u00a0without VC backing.<\/p>\n

—Cooley Godward Kronish’s<\/strong> Venture Financing Report for the fourth quarter of 2009 concludes <\/a>that while valuations remain below their historical levels, the overall trend looks promising.<\/p>\n

—Biofuels developer Synthetic Genomics<\/strong> recruited a top executive <\/a>from San Diego-based tools company Illumina<\/strong> (NASDAQ: ILMN<\/a>) as its chief operating officer.<\/p>\n

—ProActa<\/strong>, which is developing an anti-cancer drug, raised $1.1 million in debt and securities<\/a>, according to a recent regulatory filing.<\/p>\n

—SG Biofuels<\/strong>, which is a developing Jatropha as a low-cost, sustainable source of oil, announced the launch of JMax 100, <\/a>a high-yield proprietary cultivar of Jatropha optimized for growing conditions in Guatemala.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Life Sciences, Biotech Denise Gellene wrote: There was a smorgasbord of announcements in the last week. Get your fill here. —Anadys Pharmaceuticals (NASDAQ: ANDS) said preliminary findings from a mid-stage trial in hepatitis C patients showed that a drug cocktail consisting of its experimental drug ANA598, interferon, and ribavirin was about as effective after […]<\/p>\n","protected":false},"author":2918,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-361215","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/361215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2918"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=361215"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/361215\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=361215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=361215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=361215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}